Alta Life Sciences and the Centre for Technological and Industrial Development (CDTI) have invested €7.6 million in the new Barcelona-based company Accure Therapeutics, which will develop a portfolio of new medicines to address CNS diseases. Accure has integrated the assets of biotech start-ups Bionure and Iproteos.
Accure has a team with consolidated experience in the pharmaceutical and biotechnology industry. It will build on existing assets to create further value for patients, doctors and shareholders.
The company will start work on three medicine programmes (ACT-01, ACT-02 and ACT-03) focusing on four CNS disorders: optic neuritis, multiple sclerosis, Parkinson’s disease and epilepsy. ACT-01 is ready for testing in a Phase II clinical study and both ACT-02 and ACT-03 in preclinical studies.
"Accure will create significant value in a CNS sector with significant market potential, and will operate according to the efficient small R&D pharma model,” said Montserrat Vendrell, managing partner at Alta Life Sciences and CataloniaBio & HealthTech board member.
CNS disorders are a leading cause of disability and a major cause of deaths worldwide, with prevalence set to increase due to the ageing population. The CNS pharmaceutical market exceeds €73 billion.
Photo: Laurent Nguyen, founder and CEO of Accure Therapeutics - © Accure
Comments